0269

Informação básica

• Disponível em:
• English
• Português

The EarlyTect Colon Cancer Test is a groundbreaking product approved by the Korea Ministry of Food and Drug Safety. It has undergone extensive clinical trials at esteemed medical institutions such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center. These trials involved 585 men and women aged 30 to 80, and the results have proven its effectiveness.

This qualitative real-time PCR test utilizes the measurement of methylated Syndecan-2, a biomarker that is clinically associated with precancerous lesions of colorectal cancer, in stool DNA. By detecting this biomarker, the EarlyTect Colon Cancer Test can diagnose colorectal cancer with an impressive 90% sensitivity and specificity.

It's important to note that the purpose of this product is to aid in the early detection of colorectal cancer, not to confirm its presence. If a subject tests positive, it indicates the possibility of colorectal cancer or precancerous lesions of colorectal cancer.

Product Standard:

- Cancer Type: Colorectal Cancer
- Subject: Asymptomatic individuals for colorectal cancer screening
- Biomarker: SDC2 methylation

The price and transaction conditions for the EarlyTect Colon Cancer Test are open to negotiation. For further information and to request a quote, please contact us.